Skip to main content

Publications

What type of publication do you want to show?

2024

Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.

Saulters, E., Kennedy, P. T., Carter, R. J., Alsufyani, A., Jones, T. M., Woolley, J. F., & Dahal, L. N. (2024). Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.. Cancer research communications. doi:10.1158/2767-9764.crc-23-0299

DOI
10.1158/2767-9764.crc-23-0299
Journal article

2023

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

DOI
10.1101/2023.06.05.543731
Preprint

Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers

Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.c.6513438

DOI
10.1158/0008-5472.c.6513438
Other

Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects

DOI
10.1101/2023.01.04.522614
Preprint

2022

2021

STINGing Viral Tumors: What We Know from Head and Neck Cancers

Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2021). STINGing Viral Tumors: What We Know from Head and Neck Cancers. CANCER RESEARCH, 81(15), 3945-3952. doi:10.1158/0008-5472.CAN-21-0785

DOI
10.1158/0008-5472.CAN-21-0785
Journal article

Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia

Alsufyani, A., Alanazi, R., Woolley, J. F., & Dahal, L. N. (2021). Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia. MOLECULAR CANCER RESEARCH, 19(5), 753-756. doi:10.1158/1541-7786.MCR-20-0871

DOI
10.1158/1541-7786.MCR-20-0871
Journal article

2020

The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus

Dahal, L. N., Barker, R. N., & Ward, F. J. (2020). The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus. JOURNAL OF RHEUMATOLOGY, 47(2), 302-304. doi:10.3899/jrheum.190678

DOI
10.3899/jrheum.190678
Journal article

2019

Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia

Carter, M. J., Dahal, L. N., Cleary, K. L. S., Marshall, M. J. E., French, R. R., Beers, S. A., & Cragg, M. S. (2019). Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. In CHRONIC LYMPHOCYTIC LEUKEMIA (Vol. 1881, pp. 173-184). doi:10.1007/978-1-4939-8876-1_14

DOI
10.1007/978-1-4939-8876-1_14
Chapter

Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues

Sorrelle, N., Ganguly, D., Dominguez, A. T. A., Zhang, Y., Huang, H., Dahal, L. N., . . . Brekken, R. A. (2019). Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. JOURNAL OF IMMUNOLOGY, 202(1), 292-299. doi:10.4049/jimmunol.1800878

DOI
10.4049/jimmunol.1800878
Journal article

2018

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., . . . Beers, S. A. (2018). Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. IMMUNITY, 49(5), 958-970.e7. doi:10.1016/j.immuni.2018.09.014

DOI
10.1016/j.immuni.2018.09.014
Journal article

Hiding in Plain Sight: Soluble Immunomodulatory Receptors

Dahal, L. N., Schwarz, H., & Ward, F. J. (2018). Hiding in Plain Sight: Soluble Immunomodulatory Receptors. TRENDS IN IMMUNOLOGY, 39(10), 771-774. doi:10.1016/j.it.2018.08.004

DOI
10.1016/j.it.2018.08.004
Journal article

On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies

Ward, F. J., Dahal, L. N., & Abu-Eid, R. (2018). On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. FRONTIERS IN IMMUNOLOGY, 9, 12 pages. doi:10.3389/fimmu.2018.02182

DOI
10.3389/fimmu.2018.02182
Journal article

Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy

Dahal, L. N., Huang, C. -Y., Stopforth, R. J., Mead, A., Chan, K., Bowater, J. X., . . . Beers, S. A. (2018). Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. JOURNAL OF IMMUNOLOGY, 201(4), 1211-1221. doi:10.4049/jimmunol.1701122

DOI
10.4049/jimmunol.1701122
Journal article

UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion

Dahal, L. N., Gadd, A., Edwards, A. D., Cragg, M. S., & Beers, S. A. (2018). UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 87(6). doi:10.1111/sji.12666

DOI
10.1111/sji.12666
Journal article

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

Yu, X., Chan, H. T. C., Orr, C. M., Dadas, O., Booth, S. G., Dahal, L. N., . . . White, A. L. (2018). Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. CANCER CELL, 33(4), 664-675. doi:10.1016/j.ccell.2018.02.009

DOI
10.1016/j.ccell.2018.02.009
Journal article

New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B)

Roghanian, A., Stopforth, R. J., Dahal, L. N., & Cragg, M. S. (2018). New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B). JOURNAL OF LEUKOCYTE BIOLOGY, 103(6), 1077-1088. doi:10.1002/JLB.2MIR0917-354R

DOI
10.1002/JLB.2MIR0917-354R
Journal article

2017

The dichotomy of T helper 17 cells in cancer

Dahal, L. N. (2017). The dichotomy of T helper 17 cells in cancer. NATURE REVIEWS IMMUNOLOGY, 17(9), 592-593. doi:10.1038/nri.2017.93

DOI
10.1038/nri.2017.93
Journal article

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy

Dahal, L. N., Dou, L., Hussain, K., Liu, R., Earley, A., Cox, K. L., . . . Beers, S. A. (2017). STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research, 77(13), 3619-3631. doi:10.1158/0008-5472.CAN-16-2784

DOI
10.1158/0008-5472.CAN-16-2784
Journal article

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter

Turaj, A. H., Dahal, L. N., Beers, S. A., Cragg, M. S., & Lim, S. H. (2017). TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter. CANCER RESEARCH, 77(12), 3376-3378. doi:10.1158/0008-5472.CAN-17-0412

DOI
10.1158/0008-5472.CAN-17-0412
Journal article

PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2017). PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 31, 1423-1433. doi:10.1038/leu.2016.333

DOI
10.1038/leu.2016.333
Journal article

2016

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2016). PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.3241.3241

DOI
10.1182/blood.V128.22.3241.3241
Conference Paper

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Dahal, L. N., Basu, N., Youssef, H., Khanolkar, R. C., Barker, R. N., Erwig, L. P., & Ward, F. J. (2016). Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. ARTHRITIS RESEARCH & THERAPY, 18. doi:10.1186/s13075-016-1075-1

DOI
10.1186/s13075-016-1075-1
Journal article

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

Reddy, V., Dahal, L. N., Cragg, M. S., & Leandro, M. (2016). Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?. DRUG DISCOVERY TODAY, 21(8), 1330-1338. doi:10.1016/j.drudis.2016.06.009

DOI
10.1016/j.drudis.2016.06.009
Journal article

2015

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors

Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton-Key, M., French, R. R., . . . Cragg, M. S. (2015). Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors. JOURNAL OF IMMUNOLOGY, 195(11), 5503-5516. doi:10.4049/jimmunol.1402988

DOI
10.4049/jimmunol.1402988
Journal article

FcγR requirements leading to successful immunotherapy

Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015). FcγR requirements leading to successful immunotherapy. IMMUNOLOGICAL REVIEWS, 268(1), 104-122. doi:10.1111/imr.12342

DOI
10.1111/imr.12342
Journal article

Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

Roghanian, A., Teige, I., Martensson, L., Cox, K. L., Kovacek, M., Ljungars, A., . . . Cragg, M. S. (2015). Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. CANCER CELL, 27(04), 473-488. doi:10.1016/j.ccell.2015.03.005

DOI
10.1016/j.ccell.2015.03.005
Journal article

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

Tipton, T. R. W., Roghanian, A., Oldham, R. J., Carter, M. J., Cox, K. L., Mockridge, C. I., . . . Beers, S. A. (2015). Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. BLOOD, 125(12), 1901-1909. doi:10.1182/blood-2014-07-588376

DOI
10.1182/blood-2014-07-588376
Journal article

Rehabilitation or the death penalty: Autoimmune B cells in the dock

Dahal, L. N., & Cragg, M. S. (2015). Rehabilitation or the death penalty: Autoimmune B cells in the dock. EUROPEAN JOURNAL OF IMMUNOLOGY, 45(3), 687-691. doi:10.1002/eji.201545464

DOI
10.1002/eji.201545464
Journal article

2014

Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

Ward, F. J., Dahal, L. N., Khanolkar, R. C., Shankar, S. P., & Barker, R. N. (2014). Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. IMMUNOTHERAPY, 6(10), 1073-1084. doi:10.2217/IMT.14.73

DOI
10.2217/IMT.14.73
Journal article

Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads

Dahal, L. N., Barker, R. N., & Ward, F. J. (2014). Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads. SYSTEMIC LUPUS ERYTHEMATOSUS: METHODS AND PROTOCOLS, 1134, 237-247. doi:10.1007/978-1-4939-0326-9_18

DOI
10.1007/978-1-4939-0326-9_18
Journal article

Optimising macrophage phenotype and function for anti-tumour immunity

Dahal, L. N., Earley, A. J., Murinello, S., Teeling, J. L., Duriez, P. J., Houghton, F. D., . . . Cragg, M. S. (2014). Optimising macrophage phenotype and function for anti-tumour immunity. In IMMUNOLOGY Vol. 143 (pp. 125-126). Retrieved from https://www.webofscience.com/

Conference Paper

2013

Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.

Dahal, L. N., Hall, L. S., Barker, R. N., & Ward, F. J. (2013). Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.. Clinical and experimental immunology, 173(1), 58-66. doi:10.1111/cei.12091

DOI
10.1111/cei.12091
Journal article

The soluble isoform of CTLA-4 as a regulator of T-cell responses.

Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S. K., Kaewarpai, T., Xu, H., . . . Barker, R. N. (2013). The soluble isoform of CTLA-4 as a regulator of T-cell responses.. European journal of immunology, 43(5), 1274-1285. doi:10.1002/eji.201242529

DOI
10.1002/eji.201242529
Journal article